Table 2 Relationship between the rs4149056T > C and rs2282143C > T polymorphisms and acitretin efficacy in patients, based on PASI50.

From: Polymorphisms of SLCO1B1 rs4149056 and SLC22A1 rs2282143 are associated with responsiveness to acitretin in psoriasis patients

Phase

SLC22A1 Rs2282143C > T

SLCO1B1 Rs4149056T > C

Genotype/allele

PASI < 50

PASI > 50

P value

OR[95CI]

HWE P value

Genotype/allele

PASI < 50

PASI > 50

P value

 

HWE P value

Discovery Phase

CC

19

8

P < 0.001

OR:11.875

[2.677,52.670]

P = 0.368

TT

21

13

P = 0.007

OR:8.077

[1.523, 42.834]

P = 0.309

CT + TT

3

14 + 1

TC

2

10

C

41

30

P = 0.002

OR:6.613

[1.759, 24.866]

T

44

36

P = 0.013

OR:6.111

[1.258, 29.693]

T

3

16

C

2

10

Validation Phase

CC

47

27

P = 0.003

OR:3.656

[1.502, 8.897]

P = 0.859

TT

52

37

P = 0.003

OR:8.027

[1.681, 38.338]

P = 0.428

CT + TT

9 + 1

19 + 2

TC

4

11

C

103

73

P = 0.014

OR:2.622

[1.192, 5.764]

T

108

85

P = 0.028

OR:3.44

[1.075, 11.361]

T

11

23

C

4

11

Total samples

CC

66

35

P < 0.001

OR:5.222

[2.454, 11.111]

P = 0.702

TT

73

50

P < 0.001

OR:5.110

[1.925, 13.561]

P = 0.223

CT + TT

12 + 1

33 + 3

TC + TT

6

21

C

144

103

P < 0.001

OR:3.895

[2.011, 7.542]

T

152

121

P = 0.001

OR:4.397

[1.721, 11.235]

T

14

39

C

6

21

  1. Notes: In the discovery phase, 45/46 patients were genotyped with rs2282143C > T; in the validation phase, 104/105 patients were genotyped with rs4149056T > C.
Back to article page